UroGen Q1 2021 Earnings Report
Key Takeaways
UroGen Pharma reported a net product revenue of $7.5 million for Jelmyto in Q1 2021. The company is progressing with its Phase 3 ATLAS trial and expanding its immuno-oncology pipeline through strategic collaborations. They also had a net loss of $25.9 million.
Jelmyto net product revenue reached $7.5 million in Q1 2021.
New patient starts in March and April 2021 saw significant increases compared to January 2021.
Phase 3 ATLAS trial enrollment is ongoing, with new sites activated in Europe.
Expanded immuno-oncology pipeline through strategic research collaborations was announced.
UroGen
UroGen
UroGen Revenue by Segment
Forward Guidance
UroGen anticipates operating expenses in the range of $155 to $165 million, including non-cash share-based compensation expense of $24 to $28 million, subject to market conditions. Additionally, the Company anticipates accruing approximately $12 to $15 million in non-operating financing expense relating to the RTW transaction, of which cash payments for 2021 will equal 9.5% of net Jelmyto sales recognized subsequent to the May 2021 closing.